Literature DB >> 14982764

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

Mathias W R Pletz1, Andres De Roux, Andreas Roth, Karl-Heinz Neumann, Harald Mauch, Hartmut Lode.   

Abstract

Moxifloxacin is the most active fluoroquinolone against Mycobacterium tuberculosis in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log(10) CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14982764      PMCID： PMC353154          DOI： 10.1128/AAC.48.3.780-782.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

2.  A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.

Authors:  F A Sirgel; P R Donald; J Odhiambo; W Githui; K C Umapathy; C N Paramasivan; C M Tam; K M Kam; C W Lam; K M Sole; D A Mitchison
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

3.  A reiterative method for calculating the early bactericidal activity of antituberculosis drugs.

Authors:  Stephen H Gillespie; Roland D Gosling; Bambos M Charalambous
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

4.  Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology. The DATRI 008 Study Group.

Authors:  R Hafner; J A Cohn; D J Wright; N E Dunlap; M J Egorin; M E Enama; K Muth; C A Peloquin; N Mor; L B Heifets
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

5.  Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.

Authors:  F Sirgel; A Venter; D Mitchison
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

6.  The early bactericidal activity of drugs in patients with pulmonary tuberculosis.

Authors:  A Jindani; V R Aber; E A Edwards; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1980-06

7.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

8.  Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis.

Authors:  Tetsuyuki Yoshimatsu; Eric Nuermberger; Sandeep Tyagi; Richard Chaisson; William Bishai; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.

Authors:  Tina Papastavros; Lisa R Dolovich; Anne Holbrook; Lori Whitehead; Mark Loeb
Journal:  CMAJ       Date:  2002-07-23       Impact factor: 8.262

10.  Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo.

Authors:  Nicolas Veziris; Chantal Truffot-Pernot; Alexandra Aubry; Vincent Jarlier; Nacer Lounis
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191
View more
  40 in total

1.  Moxifloxacin treatment of tuberculosis.

Authors:  Roland Gosling; Stephen Gillespie
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

3.  Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log Phase, Acid Phase, and Nonreplicating-Persister Phase in an In Vitro Assay.

Authors:  Carolina de Miranda Silva; Amirhossein Hajihosseini; Jenny Myrick; Jocelyn Nole; Arnold Louie; Stephan Schmidt; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 4.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 5.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

Review 6.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

7.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

8.  Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study.

Authors:  M Tobias Heinrichs; Sergo Vashakidze; Ketino Nikolaishvili; Irina Sabulua; Nestani Tukvadze; Nino Bablishvili; Shota Gogishvili; Brent P Little; Adam Bernheim; Jeannette Guarner; Charles A Peloquin; Henry M Blumberg; Hartmut Derendorf; Russell R Kempker
Journal:  J Antimicrob Chemother       Date:  2018-02-01       Impact factor: 5.790

Review 9.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 10.  Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

Authors:  Paul Van den Brande
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.